Last reviewed · How we verify
inhalation of corticosteroids
Inhaled corticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation.
Inhaled corticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation. Used for Asthma (maintenance and control), Chronic obstructive pulmonary disease (COPD), Allergic rhinitis with lower airway involvement.
At a glance
| Generic name | inhalation of corticosteroids |
|---|---|
| Sponsor | Soroka University Medical Center |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Corticosteroids are potent anti-inflammatory agents that work by entering cells and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced recruitment and activation of immune cells in the airways. Inhalation delivery targets the drug directly to the lungs, maximizing local efficacy while minimizing systemic exposure.
Approved indications
- Asthma (maintenance and control)
- Chronic obstructive pulmonary disease (COPD)
- Allergic rhinitis with lower airway involvement
Common side effects
- Oral candidiasis (thrush)
- Hoarseness
- Throat irritation
- Cough
- Dysphonia
Key clinical trials
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.
- Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma (PHASE2)
- Hydroxychloroquin (HCQ) in chILD of Genetic Defect (NA)
- Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment (PHASE3)
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- inhalation of corticosteroids CI brief — competitive landscape report
- inhalation of corticosteroids updates RSS · CI watch RSS
- Soroka University Medical Center portfolio CI